Scarica l'app Stockscreener
0.4406
3.44%
-0.0157
Bioatla Inc Borsa (BCAB) Ultime notizie
BioAtla Inc (BCAB) Could Be Worth Considering For The Next Few Weeks - Stocksregister
BioAtla announces poster presentations at 2025 AACR meeting - TipRanks
How did BioAtla Inc (BCAB) fare last session? - uspostnews.com
BCAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
BioAtla (BCAB) to Showcase Innovative Cancer Research at 2025 Co - GuruFocus
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Cancer Treatment Breakthrough: BioAtla's Novel Drug Outperforms Standard Therapy in Multiple Cancers - Stock Titan
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
BioAtla, Inc. to Present Phase 2 Trial Results of Ozuriftamab Vedotin at ASCO 2025 Annual Meeting - Nasdaq
New Phase 2 Cancer Drug Data: BioAtla's Head and Neck Cancer Treatment Results at ASCO 2025 - Stock Titan
BioAtla stock holds $1 target, Market Outperform rating By Investing.com - Investing.com Nigeria
BioAtla stock holds $1 target, Market Outperform rating - Investing.com Australia
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Norges Bank Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla's SWOT analysis: oncology biotech's stock faces pivotal year - Investing.com
BioAtla’s SWOT analysis: oncology biotech’s stock faces pivotal year By Investing.com - Investing.com South Africa
BioAtla’s SWOT analysis: oncology biotech’s stock faces pivotal year - Investing.com India
HC Wainwright Has Optimistic Outlook of BioAtla Q1 Earnings - Defense World
FY2029 Earnings Estimate for BioAtla Issued By HC Wainwright - Defense World
BioAtla (NASDAQ:BCAB) Given “Neutral” Rating at HC Wainwright - Defense World
BioAtla stock price target cut to $1 by Citizens JMP - Investing.com Australia
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
BioAtla price target lowered to $1 from $5 at Citizens JMP - TipRanks
BioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Call Transcript - MSN
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky - Yahoo Finance
BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook - TipRanks
BioAtla stock price target cut to $10 at BTIG, retains Buy rating - Investing.com Canada
BioAtla stock price target cut to $10 at BTIG, retains Buy rating By Investing.com - Investing.com South Africa
BioAtla Inc. (BCAB) reports earnings - Quartz
BioAtla, Inc. SEC 10-K Report - TradingView
BioAtla Inc: Weathering Stock Market Storms with 22.78M Market Cap - investchronicle.com
BioAtla, Inc. Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises - Investing.com India
BioAtla announces restructuring, to cut over 30% of workforce - TipRanks
BioAtla reports Q4 Net loss ($14.9M) vs ($26.9M) last year - TipRanks
Bioatla IncAnnounces 30% Workforce Reduction - MarketScreener
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - The Manila Times
Earnings Outlook For BioAtla - Benzinga
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings - Quantisnow
BioAtla, Inc. Announces Abstract Presentations at European Lung Cancer Congress and Mayo Clinic Symposium 2025 - Nasdaq
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 - Quantisnow
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):